Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPPIX.L Regulatory News (PPIX)

  • There is currently no data for PPIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

INTERIM RESULTS FOR THE HALF YEAR ENDED 30 JUNE 14

26 Aug 2014 07:00

RNS Number : 9627P
ProPhotonix Limited
26 August 2014
 

 

August 26, 2014

 

ProPhotonix Limited

 ("ProPhotonix" or "the Company")

 

INTERIM RESULTS FOR THE HALF YEAR ENDED 30 JUNE 2014

 

ProPhotonix Limited (London Stock Exchange - AIM: PPIX and PPIR, OTC: STKR), a designer and manufacturer of LED illumination systems and laser diode modules with operations in Ireland and the U.K., today announces its unaudited interim results for the six months ended June 30, 2014.

 

Financial Highlights

· Revenue increased 13% to $8.3 million (1H 2013: $7.4 million)

· Revenue increased 11% for Laser diode modules and diodes and 15% for LED systems

· Gross profit increased 8.0% to $3.2 million (1H 2013: $3.0 million)

· Gross profit margin decreased to 38.5% (1H 2013: 40.4%)

· Operating loss decreased to $0.1 million (1H 2013: loss of $1.1(1) million)

· EBITDA of $0.1 million vs. loss of $0.9(1) million in 2013

· Order bookings of $8.6 million (1H 2013: $8.4 million)

· 1.03 Book-to-Bill ratio from existing and new customers

· Percentage revenue by market sectors: industrial 74%, medical 17%, and security & defense 9%

· Percentage revenue by geography: 49% Europe, 32% North America and 19% Rest of World

· Cash balance of $0.3 million (June 30, 2013: $0.7 million); available credit lines of $1.8 million.

(1) Includes restructuring and non-recurring costs of $582,000

 

 

 

 

 

 

Tim Losik, President & CEO, Commented:

 

"During the first half 2014, the Company has experienced an improvement in business activity with order bookings through the first six months of 2014 totaling $8.6 million and the June 30, 2014 backlog of unshipped orders, $7.2 million, up 4% since December 31, 2013. The Company ended the first six months of 2014 with a book-to-bill ratio of 1.03.

 

"We produced significant improvements in the operating performance versus the first half 2013, excluding the 2013 restructuring charge of $582K, including: Loss from operations decreased 73%, EBITDA improved from an adjusted loss of $275,000 to a profit of $118,000, and Net loss decreased 52%. The improvement in operating performance is the result of increased revenue, product mix, cost reductions, and overhead absorption. The additional actions taken to reduce costs in the first half of 2014, as previously announced on May 22, 2014, will reduce our break-even point on a go forward basis. The combination of a reduced break-even point, increased sales activity and significant new business opportunities together with the business moving towards being cash flow positive, all indicate improved prospects for 2015.

 

"As stated in our annual report for 2013, customer driven product development activity continues to remain strong. We completed many of the large customer funded development initiatives that started in 2013 and expect to begin shipping production orders from these projects in late 2014 and early 2015. These potential high volume OEM (custom) applications include illuminators for the semiconductor, optical sorting, and medical markets.

 

"During the first half of 2014, we also began working on additional large customer driven non recurring engineering opportunities that we anticipate will result in significant production volumes in 2015 and beyond. These applications include products in the medical market and additional OEM (custom) applications in the optical inspection market. We recently announced two new products adding to our product portfolio, and we expect additional new product announcements during 2014."

 

Enquiries:

 

 

ProPhotonix Limited

Tim Losik, President & CEO

Tel: +1 603 870 8220

ir@prophotonix.com

 

N+1 Singer

Andrew Craig/ Ben Wright

 

Tel: +44 (0)207 496 3000

About ProPhotonix

 

ProPhotonix Limited, headquartered in Salem, New Hampshire, is an independent designer and manufacturer of diode-based laser modules and LED systems for industry leading OEMs and medical equipment companies. In addition, the Company distributes premium diodes for Oclaro, Osram, QSI, Panasonic, and Sony. The Company serves a wide range of markets including the machine vision, industrial inspection, security, and medical markets. ProPhotonix has offices and subsidiaries in the U.S., Ireland, U.K., and Europe. For more information about ProPhotonix and its innovative products, visit the Company's web site at www.prophotonix.com.

 

 

 

 

Half Year 2014 Financial Results

 

Revenue for the half year ended June 30 2014 was $8.3 million, an increase of 13% compared with $7.4 million in the same period of 2013. Gross profit was $3.2 million, an increase of 8% compared to $3.0 million in the first half of 2013. Gross profit margin decreased to 38.5% from 40.4% in the same period 2013 due to a shift in product mix. Foreign currency exchange impact on gross profit was negligible, however, operating income was negatively impacted by approximately $0.2 million.

 

Operating expenses, excluding intangible amortization charges, totaled $3.3 million versus $3.4 million in 2013 for the comparable period, excluding the one-time restructuring costs of $582K. Sales and marketing and research and development (R&D) expenses were flat in 2014 from the first half 2013 at $1.8 million, while general and administrative expenses decreased 10% over the same period, excluding the one-time restructuring charge. The operating loss was $0.1 million, as compared to a $0.5 million loss in the same period 2013, excluding the one-time restructuring charge. EBITDA was $0.1 million as compared to a loss of $0.3 million in 2013, excluding the one-time restructuring charge The net loss was $0.5 million compared to the first half 2013 net loss of $1.5 million.

 

Strategy and Markets

 

ProPhotonix consists of two business units: an LED systems manufacturing business based in Ireland (Cork), and a laser modules production and laser diode distribution division located in the United Kingdom (Hatfield Broad Oak). Company headquarters and the North American sales activities are based in Salem, New Hampshire, United States of America.

The Company is well positioned to make significant progress on its strategy to combine its expertise in two key areas of optics: LEDs and lasers. The Company intends to capitalize on increasing opportunities in this area by designing and manufacturing high value, high margin components for global manufacturers of equipment.

 

The Company has made significant investments in R&D, including expanding its R&D team, which now includes a full complement of optical, mechanical and electrical engineers and represents over 12% of the Company's total workforce of 91 employees. They are focused on continuing to develop proprietary products to meet clearly defined demand from our customers and the markets which we serve. In this regard, progress during the first half included a range of new laser module and LED OEM opportunities including development for new customer applications. Currently, the majority of the Company's R&D and product development activities are specifically tied to future customer requirements.

 

 

 

PROPHOTONIX LIMITED

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

In thousands except share and per share data

(unaudited)

 

Six Months EndedJune 30,

 

2014

 

2013

 

Revenue...............................................................................................................................................

$ 8,319

$ 7,365

Cost of sales........................................................................................................................................

(5,116)

(4,393)

 

 

Gross profit............................................................................................................................

3,203

2,972

 

 

Operating expenses:

Selling expenses..................................................................................................................................

(1,343)

(1,317)

General and administrative...................................................................................................................

(1,476)

(2,221)

Research and development.................................................................................................................

(465)

(473)

Amortization of intangibles...................................................................................................................

(61)

(60)

 

 

Total operating expenses.....................................................................................................................

(3,345)

(4,071)

 

 

Loss from operations...........................................................................................................................

(142 )

(1,099 )

Other income / (expense), net.............................................................................................................

(91)

(393)

Interest expense..................................................................................................................................

(149)

(95)

Amortization of debt discount and financing costs..............................................................................

(102)

(6)

 

 

Loss from operations before income tax provision (benefit)...............................................................

(484 )

(1,593 )

Income tax benefit................................................................................................................................

-

74

 

 

Net loss................................................................................................................................................

(484 )

(1,519 )

Other comprehensive income (loss):

Foreign currency translation...........................................................................................................

102

151

 

 

Total comprehensive loss....................................................................................................................

$ (382)

$ (1,368)

 

 

Basic and diluted net loss per share....................................................................................................

$ (0.01)

$ (0.02)

 

 

Basic and diluted weighted average shares outstanding....................................................................

83,665

76,474

 

 

 

FINANCIAL STATEMENTS

PROPHOTONIX LIMITED

 CONSOLIDATED BALANCE SHEETS

(unaudited)

 ($ in thousands except share and per share data)

 

For the Periods Ended June 30, 2014 and 2013

 

2014

 

2013

 

Assets

Current assets:

Cash and cash equivalents

$ 253

$ 726

Accounts receivable, less allowances of $35 in 2014 and $92 in 2013

2,648

2,361

Inventories

2,049

1,943

Prepaid expenses and other current assets

198

95

 

 

Total current assets

5,148

5,125

Net property, plant and equipment

230

384

Goodwill

482

460

Acquired intangible assets, net

41

156

Other long-term assets

277

448

 

 

Total assets

$ 6,178

$ 6,573

 

 

Liabilities and Stockholders' (Deficit) Equity

Current liabilities:

Revolving credit facility

$ 1,219

$ 607

Current portion of long-term debt net of unamortized discount of $18 at June 30, 2014 and $15 at June 30, 2013

570

-

Capital lease obligations

5

10

Accounts payable

1,612

1,952

Accrued expenses

985

1,755

 

 

Total current liabilities

4,391

4,324

Long-term debt, unamortized discount of $17 at June 30, 2014 and $40 at June 30, 2013

2,310

2,442

Long-term capital lease obligation, net of current portion

-

5

Other long-term liabilities

178

178

 

 

Total liabilities

6,879

6,949

 

 

Stockholders' (deficit) equity:

Common stock, par value $0.001; shares authorized 250,000,000 at June 30, 2014 and 150,000,000 at June 30, 2013; 83,665,402 shares issued and outstanding at June 30, 2014 and at June 30, 2013

84

84

Paid-in capital

111,417

111,209

Accumulated deficit

(112,158)

(112,041)

Accumulated other comprehensive income

(44)

372

 

 

Total stockholders' (deficit) equity

(701)

(376)

 

 

Total liabilities and stockholders' equity

$ 6,178

$ 6,573

 

 

 

PROPHOTONIX LIMITED

CONSOLIDATED STATEMENTS OF CASH FLOWS

In thousands

(unaudited)

 

Six Months EndedJune 30,

 

2014

 

2013

 

Operations

Net loss................................................................................................................................

$ (484)

$ (1,519)

Adjustments to reconcile net loss to net cash used in operating activities:

Stock based compensation.........................................................................................

114

75

Depreciation and amortization..................................................................................

146

167

Foreign exchange gain...............................................................................................

88

154

Amortization of debt discount and financing costs.....................................................

95

6

Loss on disposal of assets...........................................................................................

4

12

Deferred taxes...........................................................................................................

-

(74)

Provision for inventories...........................................................................................

48

77

Provision for bad debts..............................................................................................

22

62

Other change in assets and liabilities:

Accounts receivable...................................................................................................

(132)

(235)

Inventories................................................................................................................

(111)

(17)

Prepaid expenses and other current assets..................................................................

22

138

Accounts payable.......................................................................................................

82

(23)

Accrued expenses.......................................................................................................

(313)

685

 

 

Net cash used in operating activities..............................................................................

(419)

(492)

Financing

Net borrowing of revolving credit facility.............................................................................

101

(44)

Proceeds from long-term debt issuance.................................................................................

175

640

Principal repayment of long-term debt.................................................................................

(4)

(310)

Debt issuance costs...............................................................................................................

-

(358)

 

 

Net cash used in financing activities..............................................................................

272

(72)

Investing

Purchase of plant and equipment..........................................................................................

(18)

(9)

 

 

Net cash used in investing activities..............................................................................

(18)

(9)

Effect of exchange rate on cash...........................................................................................

16

21

 

 

Net change in cash and equivalents............................................................................

(149)

(552)

Cash and equivalents, beginning of period.............................................................................

402

1,278

 

 

Cash and equivalents, end of period....................................................................

$ 253

$ 726

 

 

Supplemental disclosure of cash flow information:

Cash paid for interest...........................................................................................................

$ 149

$ 70

Common stock issued in connection with financing..............................................................

$ -

$ 193

Warrants issued in connection with financing.......................................................................

$ -

$ 55

 

 

 

 

 

 

 

 

 

PROPHOTONIX LIMITED

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY / (DEFICIT)

 (in thousands)

 

 

 

Common Stock

 

Paid inCapital

 

AccumulatedDeficit

 

Accumulated Other Comprehensive Income

 

TotalStockholders'Equity (Deficit)

 

 

Shares

 

Par$0.001

 

 

 

Balance December 31, 2013

83,665

$ 84

$ 111,302

$ (111,674)

$ (146)

$ (434)

 

Net loss

(484)

(484)

 

Translation adjustment.......

102

102

 

 

Share based compensation

-

-

114

-

-

114

 

 

 

 

 

 

 

 

Balance June 30, 2014 ...

83,665

$ 84

$ 111,417

$ (112,158)

$ (44)

$ (701)

 

 

 

 

 

 

 

 

 

 

Values may not add due to rounding

 

 

Notes to unaudited Interim Results

 

Basis of Presentation

 

The Company financial reports are issued under the recognition and measurement principles of United States Generally Accepted Accounting Principles (GAAP). The Accompanying unaudited condensed consolidated financial reports reflect all adjustments of a normal recurring nature necessary for a fair statement of the (i) results of operations and comprehensive income (loss) for the six month periods ended June 30, 2014 and 2013; (ii) the financial position at June 30, 2014 and June 30, 2013; and (iii) the cash flows for the six month period ended June 30, 2014 and 2013. These interim results are not necessarily indicative of results for a full year or any other interim period.

 

 

Cautionary Statement

 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact, including without limitation, those with respect to ProPhotonix's goals, plans and strategies set forth herein are forward-looking statements. The following important factors and uncertainties, among others, could cause actual results to differ materially from those described in these forward-looking statements: uncertainty that cash balances may not be sufficient to allow ProPhotonix to meet all of its business goals; uncertainty that ProPhotonix's new products will gain market acceptance; the risk that delays and unanticipated expenses in developing new products could delay the commercial release of those products and affect revenue estimates; the risk that one of our competitors could develop and bring to market a technology that is superior to those products that we are currently developing; and ProPhotonix's ability to capitalize on its significant research and development efforts by successfully marketing those products that the Company develops. Forward-looking statements represent management's current expectations and are inherently uncertain. All Company, brand, and product names are trademarks or registered trademarks of their respective holders. ProPhotonix undertakes no duty to update any of these forward-looking statements.

 

 

 

Use of Non-GAAP Financial Measures

 

The Company provides non-GAAP financial measures, such as EBITDA, to complement its consolidated financial statements presented in accordance with GAAP. Non-GAAP financial measures do not have any standardized definition and, therefore, are unlikely to be comparable to similar measures presented by other reporting companies. These non-GAAP financial measures are intended to supplement the user's overall understanding of the Company's current financial and operating performance and its prospects for the future. Specifically, the Company believes the non-GAAP results provide useful information to both management and investors by identifying certain expenses, gains and losses that, when excluded from the GAAP results, may provide additional understanding of the Company's core operating results or business performance, which management uses to evaluate financial performance for purposes of planning for future periods. However, these non-GAAP financial measures are not intended to supersede or replace the Company's GAAP results.

 

The Company uses EBITDA (earnings before interest, taxes, depreciation, amortization, stock-based compensation and impairment charges) as a non-GAAP financial measure in this press release. A reconciliation of net loss to EBITDA for the six months ended June 30, 2014 and 2013 is as follows:

 

(in thousands)

Six Months Ended June 30,

2014

2013

Net Loss

(484)

(1,519)

Plus:

Interest and other expense, net

240

488

Amortization of debt discount and financing costs

102

6

Depreciation

85

107

Intangible asset amortization

61

60

Stock based compensation

114

75

Tax benefit

-

(74)

EBITDA gain (loss)

118

(857)

 

Restructuring and nonrecurring charges

-

582

Adjusted EBITDA gain (loss)

118

(275)

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR EANPSADFLEFF
Date   Source Headline
16th Dec 20217:00 amRNSSale of ProPhotonix and cancelation of AIM Listing
17th Nov 20217:00 amRNSNotice of GM
11th Nov 202111:05 amRNSSecond Price Monitoring Extn
11th Nov 202111:00 amRNSPrice Monitoring Extension
11th Nov 20217:00 amRNSProPhotonix Announces Merger Agreement
2nd Nov 20217:00 amRNSProPhotonix Extends COBRA HyperSpec range
14th Sep 20217:00 amRNSProPhotonix announces the new UV COBRA Cure FX4
8th Sep 20217:00 amRNS2021 Half-year Report
9th Jun 20217:00 amRNSPosting of Annual Report and Accounts
2nd Jun 20217:00 amRNSNew Wavelengths added to UVC LED System
25th Mar 20217:00 amRNSResults for the year ended December 31, 2020
26th Jan 20217:00 amRNSNew Hyperspectral COBRA MultiSpec LED Line Light
16th Nov 20202:05 pmRNSSecond Price Monitoring Extn
16th Nov 20202:00 pmRNSPrice Monitoring Extension
12th Nov 20207:00 amRNSAdmission of Shares
10th Nov 20207:00 amRNSProPhotonix introduces 265nm UVC LED Lamp
9th Nov 20204:45 pmRNSResult of AGM and Director / PDMR Shareholdings
9th Oct 20207:00 amRNSPOSTING OF NOTICE OF ANNUAL GENERAL MEETING
8th Oct 20207:00 amRNSNew RGB-IR & RGB-White COBRA MultiSpec Line Lights
7th Oct 20203:07 pmRNSHolding(s) in Company
10th Sep 20207:00 amRNSINTERIM RESULTS FOR HALF YEAR ENDED JUNE 30, 2020
3rd Sep 20204:40 pmRNSSecond Price Monitoring Extn
3rd Sep 20204:35 pmRNSPrice Monitoring Extension
3rd Sep 20202:05 pmRNSSecond Price Monitoring Extn
3rd Sep 20202:00 pmRNSPrice Monitoring Extension
2nd Sep 20207:00 amRNSPROdigii Digital Lasers Range - 5 New Wavelengths
27th Aug 20207:00 amRNSRESULTS FOR THE YEAR ENDED DECEMBER 31, 2019
25th Aug 20201:47 pmRNSNOTICE OF EXTENSION OF RIGHTS PLAN
24th Jul 20207:00 amRNSHolding(s) in Company
16th Jul 20207:00 amRNSChange of Adviser and Director Disclosures
29th Jun 20207:00 amRNSCustom LED Backlight wins VSD Innovators Award
23rd Jun 20207:00 amRNSAccounts Reporting Extension & Trading Update
30th Apr 20207:00 amRNSDirectorate Change
9th Apr 20207:00 amRNSCOVID – 19 and Trading Update
19th Mar 20207:00 amRNS3 Year Framework Product Supply & IP Agreement
16th Mar 20207:00 amRNSProPhotonix - UV LED Water Disinfection
16th Jan 20207:00 amRNSTrading Update 2019
26th Nov 20197:00 amRNSHolding(s) in Company
10th Oct 20197:00 amRNS5-Year Master Purchase Agreement - Fortune 50 CGLM
12th Sep 20197:00 amRNSProPhotonix to Exhibit UV Lamps at Labelexpo 2019
6th Sep 20197:00 amRNSProPhotonix issues Half-year Report
3rd Sep 20197:00 amRNSNew High-Powered Red Laser Diode from Ushio
31st May 201911:59 amRNSProPhotonix Notification of Major Holdings
31st May 201911:58 amRNSProPhotonix Notification of Major Holdings
24th May 20197:00 amRNSPPIX Issues Director/PDMR Shareholding Notice
23rd May 20197:00 amRNSPPIX Issues Director/PDMR Shareholding Notice
17th May 20197:00 amRNSProPhotonix Announces Trading Update
16th May 20195:58 pmRNSPPIX Announces AGM Results and PDMR Shareholdings
16th May 20197:00 amRNSPPIX Offers New COBRA Cure Mini UV Curing System
9th Apr 20197:00 amRNSProPhotonix Honored by Vision Systems Design 2019

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.